Text Size

Effect Of Rifampin On Pharmacokinetics Of Sitaxsentan

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT01251835
First received: December 1, 2010
Last updated: January 6, 2011
Last verified: January 2011
History of Changes
  Purpose

This study will assess how rifampin will affect the blood levels of sitaxsentan. Safety of sitaxsentan given alone and with rifampin will also be assessed.


Condition Intervention Phase
Pulmonary Arterial Hypertension
 Drug: Sitaxsentan alone
Drug: Sitaxsentan
Drug: Rifampin
 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: A Phase 1, Open Label, Fixed Sequence Design, Multiple Dose Study To Assess The Effect Of Rifampin On The Pharmacokinetics Of Sitaxsentan In Healthy Subjects

Resource links provided by NLM:

Drug Information available for: Rifampin
U.S. FDA Resources

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Comparison of Peak Plasma Concentrations of sitaxsentan co-administered with rifampin versus sitaxsentan administered alone. [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
  • Comparison of Area Under the Curve of sitaxsentan co-administered with rifampin versus sitaxsentan administered alone. [ Time Frame: 24 hours ] [ Designated as safety issue: No ]

Estimated Enrollment: 16
Study Start Date: December 2010
Estimated Study Completion Date: January 2011
Estimated Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Sitaxsentan Drug: Sitaxsentan alone
Days 1-5: Sitaxsentan tablet, 100 mg, q24 h (once a day)
Experimental: Sitaxsentan plus Rifampin Drug: Sitaxsentan
Days 6-12: Sitaxsentan tablet, 100 mg, q24h (once a day)
Drug: Rifampin
Days 6-12: Rifampin capsule, 600 mg, q24h (once a day)

  Eligibility

Ages Eligible for Study:   21 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male subjects and/or women of non-child bearing potential.
  • Subjects between the ages of 21 and 55 years, inclusive.
  • Signed informed consent.

Exclusion Criteria:

  • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease.
  • Has hepatic dysfunction.
  • Has history of excessive alcohol and tobacco use.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01251835

Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
To obtain contact information for a study center near you, click here.  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc.
ClinicalTrials.gov Identifier: NCT01251835     History of Changes
Other Study ID Numbers: B1321060
Study First Received: December 1, 2010
Last Updated: January 6, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Pfizer:
Sitaxsentan
Rifampin
Drug Interaction
Pharmacokinetics

Additional relevant MeSH terms:
Hypertension, Pulmonary
Hypertension
Lung Diseases
Respiratory Tract Diseases
Vascular Diseases
Cardiovascular Diseases
Rifampin
Antibiotics, Antitubercular
Anti-Bacterial Agents
 Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Antitubercular Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Leprostatic Agents
Nucleic Acid Synthesis Inhibitors

ClinicalTrials.gov processed this record on May 19, 2013